P/E Ratio (Price-to-Earnings Ratio) in Pharmaceuticals & Healthcare
How to interpret and apply p/e ratio (price-to-earnings ratio) when analyzing pharmaceuticals & healthcare stocks in US (NYSE/Nasdaq) markets, with reference to international markets like India.
Quick Recap: What is P/E Ratio (Price-to-Earnings Ratio)?
The P/E ratio measures how much investors pay for each dollar (or rupee) of a company's earnings. It's calculated by dividing the stock price by earnings per share (EPS).
How P/E Ratio (Price-to-Earnings Ratio) Works Differently in Pharmaceuticals & Healthcare
R&D intensive, regulatory risk (USFDA), patent cliffs, mix of domestic and export revenue.
Typical Ranges for Pharmaceuticals & Healthcare
General benchmark: Varies by sector. US benchmarks: S&P 500 trailing P/E ~22, Tech (NASDAQ-100) 28-40, Financials 12-18, Consumer Staples 22-30, Energy 10-15. Or international markets like India: IT 20-35, Banking 10-20, FMCG 30-50.
Sector data last reviewed: 2026-04
Example Pharmaceuticals & Healthcare Companies to Analyze
Filter pharmaceuticals & healthcare stocks by p/e ratio and other metrics:
Key Takeaways
- P/E Ratio (Price-to-Earnings Ratio) in pharmaceuticals & healthcare should be compared against sector peers in the same market (US S&P 500 / Russell or Indian NSE / BSE), not the broad market average.
- Sector characteristics: R&D intensive, regulatory risk (USFDA), patent cliffs, mix of domestic and export revenue.
- Cross-list peers across markets, large-cap US names often set the global benchmark, while Indian peers can trade at different multiples due to growth and liquidity differences.
- Always cross-check with other metrics. No single ratio tells the full story.